Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFevertree Regulatory News (FEVR)

Share Price Information for Fevertree (FEVR)

Share Price is delayed by 15 minutes
Get Live Data
817.50    0.00 (0.00%)
Bid:
0.00
Ask:
900.00
Spread: 82.50 (10.092%)
Market Cap: £927.49m
FEVR Live PriceLast checked at - London Stock Exchange

Intraday Fevertree Share Chart

Pre-close trading update

29 Jan 2026 07:00

RNS Number : 8094Q
Fevertree Drinks PLC
29 January 2026
Ā 

Fever-Tree Drinks plc

"Excellent strategic progress in 2025 and expect to deliver a financial performance

marginally ahead of market expectations."

Ā 

Fever-Tree Drinks plc (the "Group"), the world's leading supplier of premium carbonated mixers, today provides a pre-close trading update for the year ended 31 December 2025.

Ā 

Adjusted revenue1 and adjusted EBITDA2 for FY25 are expected to be marginally ahead of current market expectations3, based upon good momentum in the second half which has resulted in Fever-Tree brand revenue increasing by 5% in H2, and full year growth of 4% (both at constant currency). This reflects continued delivery against the Group's strategic priorities and ongoing strong market share performance. In the US, the transition into Molson Coors' national distribution network is progressing to plan and, alongside an upweighted marketing investment, will provide a strong platform for 2026.

Ā 

Following the £100m share buyback programme undertaken during 2025, the previously announced additional £30m share buyback tranche will commence in February 2026.

Ā 

Ā£m

FY25

Ā£m

FY24

Ā£m

% change

Ā 

% change (CC)*

US

131.9

128.0

3%

6%

UK

108.4

111.1

(2%)

Europe Fever-Tree brand revenue

94.7

92.7

2%

2%

ROW

37.7

32.2

17%

22%

Total Adjusted Fever-Tree Revenue1

372.7

364.0

2%

4%

GDP brand revenue

2.6

4.5

(42%)

(43%)

Total Adjusted Revenue

375.3

368.5

2%

3%

*Constant Currency (CC).1. Adjusted Revenue is statutory reported revenue adjusted to bring US revenue in line with invoiced sales to customers.2. Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share-based payment charges, exceptional items and finance costs. As disclosed in September 2025, the Company has not provided for certain costs related to UK Extended Producer Responsibility levy, and continues to engage with the Environment Agency on the same.3. Company collated consensus FY25 adjusted revenue £372.4m and adjusted EBITDA £44.4m. FY26 adjusted revenue consensus £409.4m (current range £392.4m to £429.0m)) and adjusted EBITDA consensus £49.9m (current range £43.7m to £53.8m)

2025 Highlights:

Ā· US revenue +6%*. The integration of Fever-Tree into Molson Coors' national network of distributors has progressed well through the year, with continued positive brand momentum.

Ā· UK revenue -2%. Trading notably improved in the second half, driven by a robust Off-Trade performance with increasing momentum across the Group's portfolio beyond tonic, particularly our premium soft drink range.

Ā· Europe revenue +2%*. Growth was led by a strong performance in France and Benelux, as the Group continued to execute its strategy across the region.

Ā· ROW +22%* reflecting particularly strong growth in Australia, New Zealand and Canada as well as some beneficial phasing of orders.

Ā 

Outlook

We remain comfortable with current 2026 market expectations.

Tim Warrillow, CEO of Fever-Tree commented:

"We made excellent progress in 2025. Our partnership with Molson Coors in the US is progressing well, and the momentum behind the brand is especially encouraging, giving us confidence in the growing opportunity in our largest market as execution moves beyond the transition phase.

Across all our markets, we are continuing to build momentum as we broaden Fever-Tree beyond tonic, positioning the brand as not only the premium mixer but also premium soft drink of choice. We are uniquely positioned to unlock the growth opportunities afforded by the consumer trends towards moderation, premiumisation and longer, lighter serves. With exciting marketing campaigns and a strong innovation pipeline, delivered by our passionate team, I am confident we will drive strong growth in 2026 and beyond."

Next Scheduled Announcement

The Group will announce its Preliminary Results on 24 March 2026.

Ā 

For more information please contact:

Investor queries

Steve Nightingale, Investor Relations Director I steve.nightingale@fever-tree.com I +44 (0)7951 849 564

Media queries

Oliver Winters, Director of Communications I oliver.winters@fever-tree.com I +44 (0)770 332 9024

Ā 

Nominated Advisor and Broker - Investec Bank plc

David Flin I +44 (0)20 7597 5970

Corporate Broker - Jefferies International Limited

Ed Matthews I +44 (0)20 7029 8000

Financial PR advisers - FGS Global

Faeth Birch +44 (0)7768 943 171; Anjali Unnikrishnan +44 (0) 7826 534 233

Ā 

Ā 

Notes to the Editors:

Fever-Tree is the world's leading supplier of premium carbonated mixers by retail sales value, with distribution to over 95 countries worldwide. Based in the UK, the brand was launched in 2005 to provide high quality mixers which could cater to the growing demand for premium spirits, in particular gin, but also increasingly for vodka, rum and whisky. The Company now sells a range of carbonated mixers and soft drinks to hotels, restaurants, bars and cafes ("On Trade") as well as a broad range of retail outlets ("Off Trade").

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
TSTFLFLALRITFIR
Date   Source Headline
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20255:22 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20257:00 amRNSTotal Voting Rights
31st Oct 20257:00 amRNSTransaction in Own Shares
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSTransaction in Own Shares
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20253:35 pmRNSDirector/PDMR Shareholding
17th Oct 20251:19 pmRNSResults of General Meeting
16th Oct 20257:00 amRNSTransaction in Own Shares
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 20257:00 amRNSTransaction in Own Shares
13th Oct 20257:00 amRNSTransaction in Own Shares
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 20254:25 pmRNSHolding(s) in Company
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20253:06 pmRNSTR-1: Notification of major holdings
1st Oct 20258:27 amRNSTotal Voting Rights
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20259:39 amRNSHolding(s) in Company
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 202512:03 pmRNSDirector/PDMR Shareholding
11th Sep 20258:00 amRNSProposed Share Premium Cancellation
11th Sep 20257:00 amRNSFY25 Interim Results to 30 June 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.